Fax: (915) 783-1709
AMIGAS: A multicity, multicomponent cervical cancer prevention trial among Mexican American women†
Article first published online: 21 DEC 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 7, pages 1365–1372, 1 April 2013
How to Cite
Byrd, T. L., Wilson, K. M., Smith, J. L., Coronado, G., Vernon, S. W., Fernandez-Esquer, M. E., Thompson, B., Ortiz, M., Lairson, D. and Fernandez, M. E. (2013), AMIGAS: A multicity, multicomponent cervical cancer prevention trial among Mexican American women. Cancer, 119: 1365–1372. doi: 10.1002/cncr.27926
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
- Issue published online: 18 MAR 2013
- Article first published online: 21 DEC 2012
- Manuscript Accepted: 2 NOV 2012
- Manuscript Revised: 22 OCT 2012
- Manuscript Received: 31 AUG 2012
- uterine cervical cancer screening;
- Mexican origin;
- clinical trial;
- health education;
- Hispanic women
Considerable efforts have been undertaken in the United States to reduce cervical cancer incidence and mortality by increasing screening; however, disparities in screening rates continue to exist among certain racial and ethnic minority groups. The objective of the current study was to determine the effectiveness of a lay health worker-delivered intervention—AMIGAS (Ayudando a las Mujeres con Informacion, Guia, y Amor para su Salud [helping women with information, guidance, and love for their health])—to increase Papanicolaou (Pap) test screening among 3 populations of women of Mexican origin.
Six hundred thirteen women of Mexican origin in 3 treatment sites were randomized among 4 study arms: the full AMIGAS program with a video and a flip chart (n = 151), the AMIGAS program without the video (n = 154), the AMIGAS program without the flip chart (n = 155), and a usual care control group (n = 153). Six months after enrollment, women were surveyed and reported whether or not they had been screened.
Women in any of the intervention arms were statistically significantly more likely to report being screened than those in the usual care group in both an intent-to-treat analysis and a per-protocol analysis. In the intent-to-treat analysis, 25% of women in the control group and 52% in the full AMIGAS program group reported having had Pap tests (P < .001); in the per-protocol analysis, the percentages were 29% and 62%, respectively (P < .001).
AMIGAS was effective in increasing Pap test screening among women of Mexican descent when used in a 1-to-1 setting. Future research should compare the 1-on-1 intervention with the group-based intervention. Cancer 2013. © 2012 American Cancer Society.